Header Logo

Connection

MURALI CHINTAGUMPALA to Adolescent

Back to Details
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Adolescent.
MURALI CHINTAGUMPALA
Connection Strength
1.406
Adolescent
  1. Improving Time to Antibiotic Administration for Pediatric Oncology Patients With New-Onset Fever. JCO Oncol Pract. 2024 May; 20(5):725-731.
    View in: PubMed
    Score: 0.064
  2. Treatment age and neurocognitive outcomes following proton beam radiotherapy for pediatric low- and intermediate-grade gliomas. Pediatr Blood Cancer. 2021 08; 68(8):e29096.
    View in: PubMed
    Score: 0.053
  3. A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231). Pediatr Blood Cancer. 2020 09; 67(9):e28502.
    View in: PubMed
    Score: 0.050
  4. Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019 05 06; 21(5):686-695.
    View in: PubMed
    Score: 0.046
  5. Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma. Pediatr Hematol Oncol. 2018 May; 35(4):257-267.
    View in: PubMed
    Score: 0.045
  6. Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy. Radiother Oncol. 2018 07; 128(1):128-132.
    View in: PubMed
    Score: 0.042
  7. Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy. Cancer. 2017 Jul 01; 123(13):2570-2578.
    View in: PubMed
    Score: 0.039
  8. Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol. 2017 03; 39(2):97-102.
    View in: PubMed
    Score: 0.039
  9. Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):465-70.
    View in: PubMed
    Score: 0.036
  10. Risk-Based Therapy for Localized Osteosarcoma. Pediatr Blood Cancer. 2016 Mar; 63(3):412-7.
    View in: PubMed
    Score: 0.036
  11. Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma. Cancer. 2013 Jul 15; 119(14):2654-9.
    View in: PubMed
    Score: 0.030
  12. Long-term outcome of centrally located low-grade glioma in children. Cancer. 2013 Jul 15; 119(14):2630-8.
    View in: PubMed
    Score: 0.030
  13. Targeted therapy in bone and soft tissue sarcoma in children and adolescents. Curr Oncol Rep. 2012 Apr; 14(2):197-205.
    View in: PubMed
    Score: 0.028
  14. Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2011 Feb 01; 117(3):635-41.
    View in: PubMed
    Score: 0.025
  15. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
    View in: PubMed
    Score: 0.024
  16. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol. 2009 Feb; 11(1):33-40.
    View in: PubMed
    Score: 0.022
  17. Changes mimicking new leptomeningeal disease after intensity-modulated radiotherapy for medulloblastoma. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):214-21.
    View in: PubMed
    Score: 0.021
  18. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
    View in: PubMed
    Score: 0.018
  19. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
    View in: PubMed
    Score: 0.017
  20. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
    View in: PubMed
    Score: 0.017
  21. A Case Series of Children With Medulloblastoma Depicting the Disparities in Care and the Challenges in the Detection and Treatment of Pediatric Central Nervous System Tumors in Low-Resource Settings: A Case Study of Uganda. Pediatr Neurol. 2024 Dec; 161:67-72.
    View in: PubMed
    Score: 0.017
  22. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
    View in: PubMed
    Score: 0.016
  23. Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma. Pediatr Blood Cancer. 2024 Jul; 71(7):e31022.
    View in: PubMed
    Score: 0.016
  24. Adaptive, behavioral, and emotional outcomes following postoperative pediatric cerebellar mutism syndrome in survivors treated for medulloblastoma. J Neurosurg Pediatr. 2024 Jun 01; 33(6):516-523.
    View in: PubMed
    Score: 0.016
  25. Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. J Neurooncol. 2023 Jul; 163(3):717-726.
    View in: PubMed
    Score: 0.015
  26. Multi-institutional Characterization of Outcomes for Pediatric and Young Adult Patients With High-Risk Myxopapillary Ependymoma After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1174-1180.
    View in: PubMed
    Score: 0.015
  27. Characteristics of patients =10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022 01 05; 24(1):141-152.
    View in: PubMed
    Score: 0.014
  28. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
    View in: PubMed
    Score: 0.013
  29. Maternal and perinatal factors are associated with risk of pediatric central nervous system tumors and poorer survival after diagnosis. Sci Rep. 2021 05 17; 11(1):10410.
    View in: PubMed
    Score: 0.013
  30. Cognitive Risk in Survivors of Pediatric Brain Tumors. J Clin Oncol. 2021 06 01; 39(16):1718-1726.
    View in: PubMed
    Score: 0.013
  31. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):718-725.
    View in: PubMed
    Score: 0.013
  32. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021 03 01; 39(7):822-835.
    View in: PubMed
    Score: 0.013
  33. Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis. Pediatr Blood Cancer. 2020 08; 67(8):e28373.
    View in: PubMed
    Score: 0.012
  34. Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol. 2020 02; 139(2):259-271.
    View in: PubMed
    Score: 0.012
  35. Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. J Neurooncol. 2020 Jan; 146(1):147-156.
    View in: PubMed
    Score: 0.012
  36. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol. 2020 02 10; 38(5):454-461.
    View in: PubMed
    Score: 0.012
  37. Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy. Pediatr Blood Cancer. 2020 02; 67(2):e28064.
    View in: PubMed
    Score: 0.012
  38. Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only. Neuro Oncol. 2019 06 10; 21(6):809-818.
    View in: PubMed
    Score: 0.012
  39. Adaptive functioning in pediatric brain tumor survivors: An examination of ethnicity and socioeconomic status. Pediatr Blood Cancer. 2019 09; 66(9):e27800.
    View in: PubMed
    Score: 0.011
  40. Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma. Radiother Oncol. 2019 05; 134:143-150.
    View in: PubMed
    Score: 0.011
  41. Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma. Cancer Epidemiol. 2019 04; 59:71-74.
    View in: PubMed
    Score: 0.011
  42. Gastrointestinal autonomic nerve tumors in the pediatric population: a report of four cases and a review of the literature. Cancer. 1999 Jan 01; 85(1):220-30.
    View in: PubMed
    Score: 0.011
  43. Pediatric Bronchial Carcinoid Tumors: A Case Series and Review of the Literature. J Pediatr Hematol Oncol. 2019 01; 41(1):67-70.
    View in: PubMed
    Score: 0.011
  44. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018 07 01; 36(19):1963-1972.
    View in: PubMed
    Score: 0.011
  45. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798.
    View in: PubMed
    Score: 0.011
  46. Meta-analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma. Pediatr Blood Cancer. 2018 08; 65(8):e27095.
    View in: PubMed
    Score: 0.011
  47. A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018 Feb; 65(2).
    View in: PubMed
    Score: 0.010
  48. DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
    View in: PubMed
    Score: 0.010
  49. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg. 2017 09; 266(3):470-478.
    View in: PubMed
    Score: 0.010
  50. Attention, processing speed, and executive functioning in pediatric brain tumor survivors treated with proton beam radiation therapy. Radiother Oncol. 2017 07; 124(1):89-97.
    View in: PubMed
    Score: 0.010
  51. Myofibroma in Infancy and Childhood. J Pediatr Hematol Oncol. 2017 04; 39(3):e136-e139.
    View in: PubMed
    Score: 0.010
  52. Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol. 2016 10; 44:161-166.
    View in: PubMed
    Score: 0.010
  53. Mixed neuronal-glial tumors (gangliogliomas) in children. Pediatr Neurosurg. 1996 Jun; 24(6):306-13.
    View in: PubMed
    Score: 0.009
  54. Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma. J Neurooncol. 2016 05; 128(1):47-56.
    View in: PubMed
    Score: 0.009
  55. Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors. J Clin Oncol. 2016 Apr 01; 34(10):1043-9.
    View in: PubMed
    Score: 0.009
  56. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol. 2015 Nov; 125(2):307-15.
    View in: PubMed
    Score: 0.009
  57. Treatment of essential thrombocythemia with anagrelide. J Pediatr. 1995 Sep; 127(3):495-8.
    View in: PubMed
    Score: 0.009
  58. Mucoepidermoid Carcinoma in Children: A Single Institutional Experience. Pediatr Blood Cancer. 2016 Jan; 63(1):27-31.
    View in: PubMed
    Score: 0.009
  59. Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):47-53.
    View in: PubMed
    Score: 0.009
  60. Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):54-63.
    View in: PubMed
    Score: 0.009
  61. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer. J Neurosurg Pediatr. 2015 Jul; 16(1):4-13.
    View in: PubMed
    Score: 0.009
  62. Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiother Oncol. 2015 Feb; 114(2):224-9.
    View in: PubMed
    Score: 0.008
  63. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
    View in: PubMed
    Score: 0.008
  64. A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. Neuro Oncol. 2014 Jun; 16(6):787-99.
    View in: PubMed
    Score: 0.008
  65. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol. 2014 Jun; 16(6):848-55.
    View in: PubMed
    Score: 0.008
  66. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer. 2014 Apr; 61(4):601-5.
    View in: PubMed
    Score: 0.008
  67. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013 Nov 15; 19(22):6305-12.
    View in: PubMed
    Score: 0.008
  68. Integrated multimodal genetic testing of Ewing sarcoma--a single-institution experience. Hum Pathol. 2013 Oct; 44(10):2010-9.
    View in: PubMed
    Score: 0.008
  69. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol. 2013 Jun; 15(6):759-66.
    View in: PubMed
    Score: 0.008
  70. Implications of tumor location on subtypes of medulloblastoma. Pediatr Blood Cancer. 2013 Sep; 60(9):1408-10.
    View in: PubMed
    Score: 0.007
  71. Sinonasal teratocarcinosarcoma in an adolescent male. J Pediatr Hematol Oncol. 2012 Oct; 34(7):e304-7.
    View in: PubMed
    Score: 0.007
  72. Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. Pediatr Hematol Oncol. 2012 Nov; 29(8):679-85.
    View in: PubMed
    Score: 0.007
  73. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):350-4.
    View in: PubMed
    Score: 0.007
  74. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol. 2011 Jun 02; 6:58.
    View in: PubMed
    Score: 0.007
  75. Plasma proteome predicts chemotherapy response in osteosarcoma patients. Oncol Rep. 2011 Feb; 25(2):303-14.
    View in: PubMed
    Score: 0.006
  76. Low-grade myofibroblastic sarcoma of the sacrum. J Neurosurg Pediatr. 2010 Sep; 6(3):286-90.
    View in: PubMed
    Score: 0.006
  77. Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer. 2011 Jan 01; 117(1):207-17.
    View in: PubMed
    Score: 0.006
  78. Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma. Pediatr Blood Cancer. 2008 Aug; 51(2):275-9.
    View in: PubMed
    Score: 0.005
  79. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008 Aug 01; 26(22):3749-55.
    View in: PubMed
    Score: 0.005
  80. Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):173-7.
    View in: PubMed
    Score: 0.005
  81. Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer. 2008 May; 50(5):958-64.
    View in: PubMed
    Score: 0.005
  82. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 2008 Jun; 26(6):1414-24.
    View in: PubMed
    Score: 0.005
  83. Intensity-modulated radiation therapy in childhood ependymoma. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):987-93.
    View in: PubMed
    Score: 0.005
  84. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):782-7.
    View in: PubMed
    Score: 0.005
  85. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J Neurooncol. 2008 Jan; 86(2):183-90.
    View in: PubMed
    Score: 0.005
  86. A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007 Jul; 29(7):500-5.
    View in: PubMed
    Score: 0.005
  87. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol. 2007 Nov; 85(2):111-22.
    View in: PubMed
    Score: 0.005
  88. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006 Oct; 7(10):813-20.
    View in: PubMed
    Score: 0.005
  89. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006 Jun; 6(11):3426-35.
    View in: PubMed
    Score: 0.005
  90. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006 Apr 20; 24(12):1924-31.
    View in: PubMed
    Score: 0.005
  91. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006 Feb; 76(3):313-9.
    View in: PubMed
    Score: 0.005
  92. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50.
    View in: PubMed
    Score: 0.004
  93. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005 Aug 20; 23(24):5511-9.
    View in: PubMed
    Score: 0.004
  94. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005 Jan 01; 103(1):133-9.
    View in: PubMed
    Score: 0.004
  95. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res. 2005 Jan 01; 65(1):76-84.
    View in: PubMed
    Score: 0.004
  96. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol. 2004 Nov 15; 22(22):4551-60.
    View in: PubMed
    Score: 0.004
  97. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004 Aug 15; 22(16):3357-65.
    View in: PubMed
    Score: 0.004
  98. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004 Mar 15; 22(6):984-93.
    View in: PubMed
    Score: 0.004
  99. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer. 2004 Jan; 39(1):11-21.
    View in: PubMed
    Score: 0.004
  100. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003 May 07; 95(9):669-74.
    View in: PubMed
    Score: 0.004
  101. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer. 2003 May 01; 97(9 Suppl):2374-80.
    View in: PubMed
    Score: 0.004
  102. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002 Jul; 8(7):2202-9.
    View in: PubMed
    Score: 0.004
  103. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002 Mar 01; 52(3):599-605.
    View in: PubMed
    Score: 0.003
  104. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet. 2001 Jul 22; 102(1):11-7.
    View in: PubMed
    Score: 0.003
  105. Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period. J Pediatr Surg. 2001 May; 36(5):693-9.
    View in: PubMed
    Score: 0.003
  106. Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol. 2001 Jan; 20(1):75-86.
    View in: PubMed
    Score: 0.003
  107. Malignant melanoma of soft parts involving the head and neck region: review of literature and case report. Ultrastruct Pathol. 1995 Sep-Oct; 19(5):395-400.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.